Manufacturer of Controlled Substances; Notice of Registration, 69466-69467 [2010-28515]
Download as PDF
<![CDATA[
69466
Federal Register / Vol. 75, No. 218 / Friday, November 12, 2010 / Notices
Drug
Schedule
Fentanyl (9801) ...........................................................................................................................................................................................
The company plans to manufacture
small quantities of the listed controlled
substances to make reference standards
which will be distributed to their
customers.
Any other such applicant, and any
person who is presently registered with
DEA to manufacture such substances,
may file comments or objections to the
issuance of the proposed registration
pursuant to 21 CFR 1301.33(a).
Any such written comments or
objections should be addressed, in
quintuplicate, to the Drug Enforcement
Administration, Office of Diversion
Control, Federal Register Representative
(ODL), 8701 Morrissette Drive,
Springfield, Virginia 22152; and must be
filed no later than January 11, 2011.
Dated: November 1, 2010.
Joseph T. Rannazzisi,
Deputy Assistant Administrator, Office of
Diversion Control, Drug Enforcement
Administration.
factors in 21 U.S.C. 823(a) and
determined that the registration of
Lonza Riverside to manufacture the
listed basic classes of controlled
substances is consistent with the public
interest at this time. DEA has
investigated Lonza Riverside to ensure
that the company’s registration is
consistent with the public interest. The
investigation has included inspection
and testing of the company’s physical
security systems, verification of the
company’s compliance with state and
local laws, and a review of the
company’s background and history.
Therefore, pursuant to 21 U.S.C. 823(a),
and in accordance with 21 CFR 1301.33,
the above named company is granted
registration as a bulk manufacturer of
the basic classes of controlled
substances listed.
Dated: November 1, 2010.
Joseph T. Rannazzisi,
Deputy Assistant Administrator, Office of
Diversion Control, Drug Enforcement
Administration.
[FR Doc. 2010–28516 Filed 11–10–10; 8:45 am]
BILLING CODE 4410–09–P
[FR Doc. 2010–28518 Filed 11–10–10; 8:45 am]
BILLING CODE 4410–09–P
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
DEPARTMENT OF JUSTICE
Manufacturer of Controlled
Substances; Notice of Registration
Drug Enforcement Administration
Manufacturer of Controlled
Substances; Notice of Registration
By Notice dated April 26, 2010, and
published in the Federal Register on
April 30, 2010 (75 FR 22844), Lonza
Riverside, 900 River Road,
Conshohocken, Pennsylvania 19428,
made application by renewal to the
Drug Enforcement Administration
(DEA) to be registered as a bulk
manufacturer of the basic classes of
controlled substances listed in
schedules I and II:
Drug
Schedule
mstockstill on DSKH9S0YB1PROD with NOTICES
Gamma
hydroxybutyric
acid
(2010).
Amphetamine (1100) ....................
Methylphenidate (1724) ................
By Notice dated March 29, 2010, and
published in the Federal Register on
April 16, 2010, (75 FR 20001), Siemens
Healthcare Diagnostics Inc., Attn: RA,
100 GBC Drive, Mail Stop 514, Newark,
Delaware 19702, made application by
renewal to the Drug Enforcement
Administration (DEA) to be registered as
a bulk manufacturer of the basic classes
of controlled substances listed in
schedules I and II:
I
Drug
II
II
Tetrahydrocannabinols (7370) .....
Ecgonine (9180) ...........................
Morphine (9300) ...........................
The company plans to manufacture
bulk active pharmaceutical ingredients
(API’s) for distribution to its customers.
No comments or objections have been
received. DEA has considered the
Schedule
I
II
II
The company utilizes the listed
controlled substances in bulk to
manufacture in-vitro diagnostic test kits.
The company distributes the test kits for
sale to its customers. The process used
in manufacturing the test kits
irreversibly alters the controlled
substances involved in such a manner
that they are no longer classified as
controlled substances as defined under
the Controlled Substances Act.
No comments or objections have been
received. DEA has considered the
factors in 21 U.S.C. 823(a) and
determined that the registration of
Siemens Healthcare Diagnostics Inc. to
manufacture the listed basic classes of
controlled substances is consistent with
the public interest at this time. DEA has
investigated Siemens Healthcare
Diagnostics Inc. to ensure that the
company’s registration is consistent
with the public interest. The
investigation has included inspection
and testing of the company’s physical
security systems, verification of the
company’s compliance with state and
local laws, and a review of the
company’s background and history.
Therefore, pursuant to 21 U.S.C. 823(a),
and in accordance with 21 CFR 1301.33,
the above named company is granted
registration as a bulk manufacturer of
the basic classes of controlled
substances listed.
Dated: November 1, 2010.
Joseph T. Rannazzisi,
Deputy Assistant Administrator, Office of
Diversion Control, Drug Enforcement
Administration.
[FR Doc. 2010–28531 Filed 11–10–10; 8:45 am]
BILLING CODE 4410–09–P
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
Manufacturer of Controlled
Substances; Notice of Registration
By Notice dated June 17, 2010, and
published in the Federal Register on
June 28, 2010, (75 FR 36684), Varian
Inc., 25200 Commercentre Drive, Lake
Forest, California 92630–8810, made
application by renewal to the Drug
Enforcement Administration (DEA) to
be registered as a bulk manufacturer of
the basic classes of controlled
substances listed in schedule II:
Drug
Schedule
Phencyclidine (7471) ...................................................................................................................................................................................
1-Piperidinocyclohexanecarbonitrile (8603) ................................................................................................................................................
VerDate Mar<15>2010
17:23 Nov 10, 2010
Jkt 223001
PO 00000
Frm 00071
Fmt 4703
II
Sfmt 4703
E:\FR\FM\12NON1.SGM
12NON1
II
II
69467
Federal Register / Vol. 75, No. 218 / Friday, November 12, 2010 / Notices
Drug
Schedule
Benzoylecgonine (9180) ..............................................................................................................................................................................
The company plans to manufacture
small quantities of the listed controlled
substances for use in diagnostic
products.
No comments or objections have been
received. DEA has considered the
factors in 21 U.S.C. 823(a) and
determined that the registration of
Varian Inc., to manufacture the listed
basic classes of controlled substances is
consistent with the public interest at
this time. DEA has investigated Varian
Inc., to ensure that the company’s
registration is consistent with the public
interest. The investigation has included
inspection and testing of the company’s
physical security systems, verification
of the company’s compliance with state
and local laws, and a review of the
company’s background and history.
Therefore, pursuant to 21 U.S.C. 823(a),
and in accordance with 21 CFR 1301.33,
the above named company is granted
registration as a bulk manufacturer of
the basic classes of controlled
substances listed.
Dated: November 1, 2010.
Joseph T. Rannazzisi,
Deputy Assistant Administrator, Office of
Diversion Control, Drug Enforcement
Administration.
[FR Doc. 2010–28515 Filed 11–10–10; 8:45 am]
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
mstockstill on DSKH9S0YB1PROD with NOTICES
VerDate Mar<15>2010
17:23 Nov 10, 2010
Schedule
Jkt 223001
II
II
The company plans to manufacture
the listed controlled substances as bulk
controlled substance intermediates for
distribution to its customers.
No comments or objections have been
received. DEA has considered the
factors in 21 U.S.C. 823(a) and
determined that the registration of
Penick Corporation to manufacture the
listed basic classes of controlled
substances is consistent with the public
interest at this time. DEA has
investigated Penick Corporation to
ensure that the company’s registration is
consistent with the public interest. The
investigation has included inspection
and testing of the company’s physical
security systems, verification of the
company’s compliance with state and
local laws, and a review of the
company’s background and history.
Therefore, pursuant to 21 U.S.C. 823(a),
and in accordance with 21 CFR 1301.33,
the above named company is granted
registration as a bulk manufacturer of
the basic classes of controlled
substances listed.
BILLING CODE 4410–09–P
By Notice dated June 17, 2010, and
published in the Federal Register on
June 28, 2010, (75 FR 36683), Penick
Corporation, 33 Industrial Road,
Pennsville, New Jersey 08070, made
application by renewal to the Drug
Enforcement Administration (DEA) to
be registered as a bulk manufacturer of
the basic classes of controlled
substances listed in schedule II:
II
II
II
II
II
II
II
II
II
II
Thebaine (9333) ...........................
Oxymorphone (9652) ...................
[FR Doc. 2010–28533 Filed 11–10–10; 8:45 am]
Manufacturer of Controlled
Substances; Notice of Registration
Cocaine (9041) .............................
Codeine (9050) .............................
Dihydrocodeine (9120) .................
Oxycodone (9143) ........................
Hydromorphone (9150) ................
Diphenoxylate (9170) ...................
Ecgonine (9180) ...........................
Hydrocodone (9193) .....................
Morphine (9300) ...........................
Oripavine (9330) ...........................
Schedule
Dated: November 1, 2010.
Joseph T. Rannazzisi,
Deputy Assistant Administrator, Office of
Diversion Control, Drug Enforcement
Administration.
BILLING CODE 4410–09–P
Drug
Drug
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
Manufacturer of Controlled
Substances; Notice of Registration
By Notice dated June 17, 2010, and
published in the Federal Register on
June 28, 2010, (75 FR 36683), Wildlife
Laboratories, Inc., 1401 Duff Drive,
Suite 400, Fort Collins, Colorado 80524,
made application by renewal to the
Drug Enforcement Administration
(DEA) to be registered as a bulk
manufacturer of Carfentanil (9743), a
basic class of controlled substance listed
in schedule II.
The company will manufacture the
above listed controlled substance for
sale to veterinary pharmacies, zoos, and
for other animal and wildlife
applications.
PO 00000
Frm 00072
Fmt 4703
Sfmt 4703
II
No comments or objections have been
received. DEA has considered the
factors in 21 U.S.C. 823(a) and
determined that the registration of
Wildlife Laboratories, Inc. to
manufacture the listed basic class of
controlled substance is consistent with
the public interest at this time. DEA has
investigated Wildlife Laboratories, Inc.
to ensure that the company’s
registration is consistent with the public
interest. The investigation has included
inspection and testing of the company’s
physical security systems, verification
of the company’s compliance with state
and local laws, and a review of the
company’s background and history.
Therefore, pursuant to 21 U.S.C. 823(a),
and in accordance with 21 CFR 1301.33,
the above named company is granted
registration as a bulk manufacturer of
the basic class of controlled substance
listed.
Dated: November 1, 2010.
Joseph T. Rannazzisi,
Deputy Assistant Administrator, Office of
Diversion Control, Drug Enforcement
Administration.
[FR Doc. 2010–28522 Filed 11–10–10; 8:45 am]
BILLING CODE 4410–09–P
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
Manufacturer of Controlled
Substances; Notice of Registration
By Notice dated March 16, 2010, and
published in the Federal Register on
March 24, 2010, (75 FR 14190),
Archimica, Inc., 2460 W. Bennett Street,
Springfield, Missouri 65807–1229, made
application by letter to the Drug
Enforcement Administration (DEA) to
be registered as a bulk manufacturer of
Gamma Hydroxybutyric Acid (2010), a
basic class of controlled substance listed
in schedule I.
The company plans to manufacture
the listed controlled substance in bulk
for sale to its customers.
One comment and objection was
received. However, after a thorough
review of this matter, DEA has
concluded that the issues raised in the
comment and objection do not warrant
the denial of this application.
DEA has considered the factors in 21
U.S.C. 823(a) and determined that the
registration of Archimica, Inc., to
manufacture the listed basic class of
controlled substance is consistent with
E:\FR\FM\12NON1.SGM
12NON1
]]>Agencies
[Federal Register Volume 75, Number 218 (Friday, November 12, 2010)]
[Notices]
[Pages 69466-69467]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: 2010-28515]
-----------------------------------------------------------------------
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
Manufacturer of Controlled Substances; Notice of Registration
By Notice dated June 17, 2010, and published in the Federal
Register on June 28, 2010, (75 FR 36684), Varian Inc., 25200
Commercentre Drive, Lake Forest, California 92630-8810, made
application by renewal to the Drug Enforcement Administration (DEA) to
be registered as a bulk manufacturer of the basic classes of controlled
substances listed in schedule II:
------------------------------------------------------------------------
Drug Schedule
------------------------------------------------------------------------
Phencyclidine (7471)............................. II
1-Piperidinocyclohexanecarbonitrile (8603)....... II
[[Page 69467]]
Benzoylecgonine (9180)........................... II
------------------------------------------------------------------------
The company plans to manufacture small quantities of the listed
controlled substances for use in diagnostic products.
No comments or objections have been received. DEA has considered
the factors in 21 U.S.C. 823(a) and determined that the registration of
Varian Inc., to manufacture the listed basic classes of controlled
substances is consistent with the public interest at this time. DEA has
investigated Varian Inc., to ensure that the company's registration is
consistent with the public interest. The investigation has included
inspection and testing of the company's physical security systems,
verification of the company's compliance with state and local laws, and
a review of the company's background and history. Therefore, pursuant
to 21 U.S.C. 823(a), and in accordance with 21 CFR 1301.33, the above
named company is granted registration as a bulk manufacturer of the
basic classes of controlled substances listed.
Dated: November 1, 2010.
Joseph T. Rannazzisi,
Deputy Assistant Administrator, Office of Diversion Control, Drug
Enforcement Administration.
[FR Doc. 2010-28515 Filed 11-10-10; 8:45 am]
BILLING CODE 4410-09-P
